GSK ready to market Amgen's new bone drug

Fresh off European approval of Amgen's (NASDAQ: AMGN) much-anticipated bone drug Prolia (denosumab), GlaxoSmithKline (NYSE: GSK) will be gearing up to collaborate with the biotech on commercializing the potential blockbuster drug in Europe. Report